Lazabemide for the treatment of Alzheimer's disease: rationale and therapeutic perspectives.

Cesura, A M; Borroni, E; Gottowik, J; Kuhn, C; Malherbe, P; Martin, J; Richards, J G

Cesura, A M; Borroni, E; Gottowik, J; Kuhn, C; Malherbe, P; Martin, J; Richards, J G.

Affiliation

Cesura AM; Pharmaceuticals Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland.

Adv Neurol ; 80: 521-8, 1999.

Article in En | MEDLINE | ID: mdl-10410766

Subject(s)

Alzheimer Disease/drug therapy; Monoamine Oxidase Inhibitors/therapeutic use; Picolinic Acids/therapeutic use; Animals; Brain/enzymology; Humans; Mice; Mice, Transgenic/metabolism; Monoamine Oxidase/drug effects; Monoamine Oxidase/metabolism; Neurodegenerative Diseases/physiopathology; Oxidative Stress/physiology

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Picolinic Acids / Alzheimer Disease / Monoamine Oxidase Inhibitors Limits: Animals / Humans Language: En Journal: Adv Neurol Year: 1999 Document type: Article Affiliation country: Switzerland

Search on Google

Add to My VHL

XML

PubMed Links